氫可酮市場規模、佔有率和成長分析（按形式、分銷管道、應用、最終用戶和地區）- 2025-2032 年產業預測

2023 年全球氫可酮市場規模價值 300.3 億美元，預計將從 2024 年的 323.4 億美元成長到 2032 年的 585.5 億美元，預測期內（2025-2032 年）的複合年成長率為 7.7%。

全球氫可酮市場是製藥業的關鍵領域，由於慢性疼痛的增加（尤其是老齡化人口）對強效止痛藥的需求不斷成長，該市場專注於提供有效的疼痛管理解決方案。氫可酮在醫院和安寧療護中心等醫療機構中仍然發揮著重要作用，因為它在緩解癌症和術後恢復等疾病相關的劇烈疼痛方面發揮作用。然而，這個市場也存在挑戰，包括濫用和成癮的潛在風險，需要醫療保健提供者的謹慎管理。儘管存在這些障礙，但技術進步、創新藥物配方和安寧療護的成長凸顯了市場擴張的巨大機會，最終有助於改善嚴重疼痛患者的生活品質。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和資料資料
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究

氫可酮市場規模（按形式和複合年成長率） (2025-2032)

• 市場概況
• 口服錠劑
• 注射
• 膠囊
• 其他

氫可酮市場規模（按分銷管道和複合年成長率） (2025-2032)

• 市場概況
• 醫院藥房
• 零售藥局
• 網路藥局
• 其他

氫可酮市場規模（按應用和複合年成長率） (2025-2032)

• 市場概況
• 疼痛管理
• 止瀉劑
• 感冒咳嗽藥
• 其他

氫可酮市場規模（依最終用戶和複合年成長率） (2025-2032)

• 市場概況
• 醫院和診所
• 門診手術中心
• 其他

氫可酮市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較（2022-2024 年）

主要企業簡介

• Pfizer Inc.（USA）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Hikma Pharmaceuticals PLC（UK）
• Mallinckrodt Pharmaceuticals（Ireland）
• Boehringer Ingelheim GmbH（Germany）
• Gerot Lannach（Austria）
• Dongbei Pharmaceutical Group Co.（China）
• Taiji Group Southwest Pharmaceutical Co.（China）
• Sun Pharmaceutical Industries Ltd.（India）
• Sanofi SA（France）
• Johnson & Johnson（USA）
• Novartis International AG（Switzerland）
• GlaxoSmithKline plc（UK）
• AstraZeneca plc（UK）
• Eli Lilly and Company（USA）
• Bayer AG（Germany）
• Roche Holding AG（Switzerland）
• Merck & Co., Inc.（USA）

結論和建議

Global Morphine Market size was valued at USD 30.03 billion in 2023 and is poised to grow from USD 32.34 billion in 2024 to USD 58.55 billion by 2032, growing at a CAGR of 7.7% during the forecast period (2025-2032).

The global morphine market, a key segment of the pharmaceutical industry, is focused on providing effective pain management solutions stemming from rising demands for potent analgesics amid increasing chronic pain conditions, particularly within the aging demographic. As morphine serves to alleviate severe pain associated with ailments like cancer and postoperative recovery, its presence in medical facilities, including hospitals and palliative care centers, remains critical. However, the market grapples with challenges such as potential abuse and addiction risk, necessitating careful management by healthcare providers. Despite these hurdles, advancements in technology, innovative drug formulations, and the growth of palliative care highlight significant opportunities for market expansion, ultimately contributing to improved quality of life for patients experiencing intense pain.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Morphine market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Morphine Market Segmental Analysis

Global Morphine Market is segmented by Form, Distribution Channel, Application, End User and region. Based on Form, the market is segmented into Oral Tablets, Injection, Capsule and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others. Based on Application, the market is segmented into Pain Management, Diarrhea Suppressant, Cold & Cough Suppressant and Others. Based on End User, the market is segmented into Hospitals & Clinics, Ambulatory Surgical Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Morphine Market

The global morphine market is significantly influenced by the rising prevalence of chronic pain disorders. An increasing number of individuals suffering from conditions such as cancer, musculoskeletal issues, and neuropathic pain is a key market driver. According to the World Health Organization's projections from 2022, the incidence of cancer cases is expected to rise by almost 50% over the next twenty years. This surge in chronic pain cases has escalated the demand for effective analgesics, particularly morphine, thereby contributing to the overall growth of the morphine market as healthcare providers seek to offer adequate pain management solutions.

Restraints in the Global Morphine Market

The global morphine market encounters significant restraints primarily due to a stringent regulatory environment that governs opioid medications. To combat the growing epidemic of opioid misuse, addiction, and overdose, governments and healthcare authorities have implemented rigorous regulations, including restrictions on prescriptions, monitoring programs, and stringent guidelines for safe usage. While these measures aim to curtail the opioid crisis, they inadvertently pose considerable challenges for manufacturers and healthcare providers, hindering compliance and limiting access to morphine for patients who genuinely require it for medical treatment. Consequently, the balance between ensuring safety and maintaining necessary availability remains a pressing issue within the sector.

Market Trends of the Global Morphine Market

The Global Morphine market is experiencing a significant trend towards personalized pain management, with a growing emphasis on individualized treatment strategies that consider patient-specific characteristics, genetics, and unique pain profiles. This paradigm shift is fueled by advances in pharmacogenomics, which enable healthcare providers to optimize opioid therapy by identifying patients at higher risk for adverse responses. Research, including a pivotal 2022 study in the Journal of Pain and Symptom Management, highlights the potential of tailored approaches to enhance therapeutic outcomes for patients requiring morphine. As the focus on precision medicine intensifies, the demand for morphine is likely to rise, particularly among targeted patient demographics.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies

Global Morphine Market Size by Form & CAGR (2025-2032)

• Market Overview
• Oral Tablets
• Injection
• Capsule
• Others

Global Morphine Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Global Morphine Market Size by Application & CAGR (2025-2032)

• Market Overview
• Pain Management
• Diarrhea Suppressant
• Cold & Cough Suppressant
• Others

Global Morphine Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others

Global Morphine Market Size & CAGR (2025-2032)

• North America (Form, Distribution Channel, Application, End User)
  • US
  • Canada
• Europe (Form, Distribution Channel, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Form, Distribution Channel, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Form, Distribution Channel, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Form, Distribution Channel, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mallinckrodt Pharmaceuticals (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gerot Lannach (Austria)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dongbei Pharmaceutical Group Co. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Taiji Group Southwest Pharmaceutical Co. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations